Journal
CUREUS JOURNAL OF MEDICAL SCIENCE
Volume 12, Issue 4, Pages -Publisher
SPRINGERNATURE
DOI: 10.7759/cureus.7586
Keywords
genitourinary syndrome of menopause; vaginal atrophy; vaginal dryness; dysparcunia; estrogen replacement therapy; laser therapy
Categories
Ask authors/readers for more resources
The genitourinary syndrome of menopause (GSM) is a relatively new term for the condition previously known as vulvovaginal atrophy, atrophic vaginitis, or urogenital atrophy. The term was first introduced in 2014. GSM is a chronic, progressive, vulvovaginal, sexual, and lower urinary tract condition characterized by a broad spectrum of signs and symptoms. Most of these symptoms can be attributed to the lack of estrogen that characterizes menopause. Even though the condition mainly affects postmenopausal women, it is seen in many premenopausal women as well. The hypoestrogenic state results in hormonal and anatomical changes in the genitourinary tract, with vaginal dryness, dyspareunia, and reduced lubrication being the most prevalent and bothersome symptoms. These can have a great impact on the quality of life (QOL) of the affected women, especially those who are sexually active. The primary goal of the treatment of GSM is to achieve the relief of symptoms. First-line treatment consists of nonhormonal therapies such as lubricants and moisturizers, while hormonal therapy with local estrogen products is generally considered the gold standard. Newer therapeutic approaches with selective estrogen receptor modulators (SERMs) or laser technologies can be employed as alternative options, but further research is required to investigate the viability and scope of their implementation in day-to-day clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available